# Myriad Genetics Inc.

**MYGN**

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0000899923

**B**

**second fifth of 369 graded peers in healthcare**

rank 104 of 369; percentile 28.0; sampling error 2.5 points; lower is stronger

A B C D E

**B, the elk**



## Scoreboard

| | |
|---|---|
| **Profitability** | A<br>percentile 8.6 |
| **Solvency** | C/D<br>percentile 58.7 |
| **Growth and financing** | C<br>percentile 56.2 |
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $706.6M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered; fortress balance sheet<br>not computable: distress |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Feb 24, 2026<br>251 days before the rescan; latest periodic filing 10-Q received Jul 31, 2026 |
| **Last close** | $6.33<br>2026-10-30; market equity $605.9M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 24, 2026*

Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all. We develop and commercialize molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. Personalized molecular data and digital and virtual consumer trends are converging to transform traditional models of care.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 8.6** | | | | | | |
| Gross profitability | 81.6% | 32.4% | | 7.7 | 366 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |
| *prior invested-capital observation is 1096 days earlier* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (42.4%) | (6.6%) | 9.5 | 803 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five consecutive annual gross margins are required* | | | | | |
| **Solvency, sleeve percentile 58.7** | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | (5.88) | (0.35) | 54.2 | 748 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *EBITDA must exceed $100,000* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | |
| Current ratio | 2.49x | 2.92x | 63.2 | 829 | 2025-12-31 |
| **Growth and financing, sleeve percentile 56.2** | | | | | |
| Revenue growth, three-year compound | 6.7% | 10.1% | 56.2 | 412 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *four consecutive annual FCF observations are required; found 12* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *NOPAT must exceed $100,000* | | | | | |
| Asset growth, three years | (16.2%) | 2.2% | 78.1 | 696 | 2025-12-31 |
| Net share issuance, one year | 2.4% | 2.5% | 34.1 | 631 | 2026-02-19 |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Fortress balance sheet | cash minus debt is 29,700,000 USD; Altman Z is not used |

## Among 369 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 99 | Sensus Healthcare, Inc. (SRTS) | 26.6 | B | |
| 100 | Travere Therapeutics, Inc. (TVTX) | 26.9 | B | |
| 101 | Tela Bio, Inc. (TELA) | 27.2 | B | fortress balance sheet |
| 102 | Staar Surgical Co. (STAA) | 27.4 | B | |
| 103 | Alphatec Holdings, Inc. (ATEC) | 27.7 | B | |
| 104 | Myriad Genetics Inc. (MYGN) | 28.0 | B | fortress balance sheet |
| 105 | Agape ATP Corp. (ATPC) | 28.3 | B | late filer |
| 106 | DocGo Inc. (DCGO) | 28.5 | B | late filer, fortress balance sheet |
| 107 | Healthcare Services Group Inc. (HCSG) | 28.8 | B | |
| 108 | Cytokinetics Inc. (CYTK) | 29.1 | B | short runway |
| 109 | Agios Pharmaceuticals, Inc. (AGIO) | 29.3 | B | short runway |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-10-30 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (46.4%) | (2.2%) | 18 |
| Distance from 52-week high | (22.4%) | (28.7%) | 58 |
| EBIT to enterprise value | (63.2%) | (1.4%) | 11 |
| Free cash flow yield | (25.0%) | (1.0%) | 22 |
| Book value to price | 0.50 | 0.28 | 71 |
| Sales to price | 1.36 | 0.30 | 87 |
| Composite equity issuance, five years | 22.6% | 20.5% | 51 |
| Relative strength against the sector, log excess return | (0.79) | (0.19) | 18 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 5 of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $115.2M |
| Operating cash flow, four quarters | $7.7M |
| Months of runway | not finite |
| Days since last periodic filing | 94 (10-Q received Jul 31, 2026) |
| Median daily dollar volume, 63 sessions | $6.8M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $576.6M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 2 | assets | us-gaap:Assets | $706.6M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 3 | operating income | us-gaap:OperatingIncomeLoss | -$387.2M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$395.1M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | -$29.2M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 6 | total debt | us-gaap:LongTermDebt | $119.9M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 7 | book equity | us-gaap:StockholdersEquity | $368.0M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $149.6M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 9 | total debt | us-gaap:LongTermDebt | $0 | 2022-12-31 | 2023-03-01 | 10-K | 23-000011 |
| 10 | book equity | us-gaap:StockholdersEquity | $885.8M | 2022-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 11 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $56.9M | 2022-12-31 | 2025-02-28 | 10-K | 25-000019 |
| 12 | net income | us-gaap:NetIncomeLoss | -$365.9M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $1.8M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 14 | assets | us-gaap:Assets | $1.0B | 2024-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 15 | current assets | us-gaap:AssetsCurrent | $332.6M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $133.8M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$1.1B | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 18 | liabilities | us-gaap:Liabilities | $338.6M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 19 | depreciation amortization | us-gaap:Depreciation | $19.5M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 20 | operating income | us-gaap:OperatingIncomeLoss | -$257.4M | 2023-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 21 | interest expense | us-gaap:InterestExpense | $2.9M | 2023-12-31 | 2024-02-28 | 10-K | 24-000018 |
| 22 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $824.5M | 2025-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $837.6M | 2024-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 24 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $753.2M | 2023-12-31 | 2026-02-24 | 10-K | 26-000018 |
| 25 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $678.4M | 2022-12-31 | 2025-02-28 | 10-K | 25-000019 |
| 26 | capital expenditure | us-gaap:PaymentsToAcquireProductiveAssets | $45.3M | 2022-12-31 | 2023-03-01 | 10-K | 23-000011 |
| 27 | depreciation amortization | us-gaap:Depreciation | $11.6M | 2022-12-31 | 2025-02-28 | 10-K | 25-000019 |
| 28 | operating income | us-gaap:OperatingIncomeLoss | -$140.6M | 2022-12-31 | 2025-02-28 | 10-K | 25-000019 |
| 29 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$140.6M | 2022-12-31 | 2025-02-28 | 10-K | 25-000019 |
| 30 | income tax | us-gaap:IncomeTaxExpenseBenefit | -$28.6M | 2022-12-31 | 2025-02-28 | 10-K | 25-000019 |
| 31 | current assets | us-gaap:AssetsCurrent | $274.6M | 2022-12-31 | 2024-02-28 | 10-K | 24-000018 |
| 32 | current liabilities | us-gaap:LiabilitiesCurrent | $137.2M | 2022-12-31 | 2024-02-28 | 10-K | 24-000018 |
| 33 | current assets | us-gaap:AssetsCurrent | $484.8M | 2021-12-31 | 2023-03-01 | 10-K | 23-000011 |
| 34 | current liabilities | us-gaap:LiabilitiesCurrent | $204.3M | 2021-12-31 | 2023-03-01 | 10-K | 23-000011 |
| 35 | assets | us-gaap:Assets | $1.1B | 2023-12-31 | 2025-02-28 | 10-K | 25-000019 |
| 36 | assets | us-gaap:Assets | $1.2B | 2022-12-31 | 2024-02-28 | 10-K | 24-000018 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 93,508,165 | 2026-02-19 | 2026-02-24 | 10-K | 26-000018 |
| 38 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 91,309,064 | 2025-02-21 | 2025-02-28 | 10-K | 25-000019 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.